Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 27;13:6385. doi: 10.1038/s41467-022-34083-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a, b Flow cytometry analyses of GPR97 and PAR2 expression in resting neutrophils treated without or with the azurophil granule degranulation stimulants (n = 4, except CD63 n = 3) a and aIgGs (GPR97 n = 3, PAR2 n = 4) b as indicated. a Samples include: 1, fresh neutrophils; 2, untreated neutrophils; 3, neutrophils treated with fMLF (1 μM) for 15 min; 4, neutrophils treated with cytochalasin B (cytoB, 5 μM) for 5 min, followed by fMLF (1 μM) for 10 min. CD63 expression was used as a degranulation marker of azurophil granule. c Relative PLA signals of indicated receptor pairs in resting (n = 3) and aIgG-treated (n = 3) neutrophils. d ELISA analyses of IL-8 secreted by neutrophils incubated for 3 h at 37 °C as indicated (n = 3). Data in a–d are presented as means ± SEM. P value was determined by two-way ANOVA in a, b, d and by one-sided unpaired student’s t-test in c. ns non-significant. e, f ELISA analyses of IL-8 secreted by neutrophils that were incubated with purified IgGs (0.5 mg/mL) from different PR3-ANCA and MPO-ANCA patients for 3 h at 37 °C as indicated. Data are presented as means ± SEM of one representative experiment done in triplicate. ENMD-1068: PAR2 antagonist; SAM11 and MAB3949: anti-PAR2 mAbs; G97-A and BGP: anti-GPR97 mAbs; 2A1: anti-EMR2 mAb. Source data are provided in the Source Data file.